MET and neoplasm: Complementary studies exploring the efficacy of combination therapy either in immunodeficient mice or in mice carrying tumors with disrupted Met gene expression confirmed that synergy requires at least two components, first, expression of MET in the tumor, second, a functional immune system (Fig. 6).